VTP 100
Alternative Names: Influenza virus vaccine - Barinthus Biotherapeutics; MVA-M1+NP; MVA-NP+M1; Universal influenza vaccine - Barinthus Biotherapeutics; VTP-100Latest Information Update: 30 Jul 2025
At a glance
- Originator Vaccitech
- Developer Barinthus Biotherapeutics
- Class Influenza virus DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 02 May 2025 Discontinued - Phase-II for Influenza A virus infections (Adjunctive treatment, In adults, In the elderly, Prevention) in Australia due to lack of efficacy (IM)
- 02 May 2025 Discontinued - Phase-II for Influenza A virus infections (Combination therapy, In the elderly, Prevention) in United Kingdom due to lack of efficacy (IM)
- 02 May 2025 Discontinued - Phase-II for Influenza A virus infections (In the elderly, Prevention) in United Kingdom due to lack of efficacy (IM)